Akeso, Inc. (HKG:9926)
Hong Kong · Delayed Price · Currency is HKD 113.40
+2.50 (2.25%)
Oct 31, 2025, 4:08 PM HKT
Akeso Employees
Akeso had 3,035 employees as of December 31, 2024. The number of employees increased by 257 or 9.25% compared to the previous year.
Employees
3,035
Change (1Y)
257
Growth (1Y)
9.25%
Revenue / Employee
779.60K HKD
Profits / Employee
-262.69K HKD
Market Cap
104.46B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3,035 | 257 | 9.25% |
| Dec 31, 2023 | 2,778 | 437 | 18.67% |
| Dec 31, 2022 | 2,341 | 476 | 25.52% |
| Dec 31, 2021 | 1,865 | 1,119 | 150.00% |
| Dec 31, 2020 | 746 | 356 | 91.28% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sino Biopharmaceutical | 24,379 |
| CSPC Pharmaceutical Group | 21,400 |
| WuXi Biologics | 12,575 |
| BeOne Medicines AG | 11,000 |
| Hansoh Pharmaceutical Group Company | 8,989 |
| Innovent Biologics | 5,659 |
| 3SBio | 5,577 |
| JD Health International | 3,564 |
Akeso News
- 11 days ago - Akeso, Inc. (AKESF) Presents at ESMO Congress 2025 - Slideshow - Seeking Alpha
- 12 days ago - China’s Akeso gets share boost as data shows cancer drug’s benefits - South China Morning Post
- 6 weeks ago - Akeso's Ligufalimab Receives FDA Orphan Drug Designation For Acute Myeloid Leukemia - Nasdaq
- 7 weeks ago - Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences - Benzinga
- 2 months ago - Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst - Benzinga
- 2 months ago - Akeso (9926.HK) Soars on Positive Lung Cancer Drug Trial Results - GuruFocus
- 2 months ago - Akeso shares surge as cancer drug achieves key milestone in China trial - Seeking Alpha
- 5 months ago - Chinese biotech firm Akeso sinks after US partner’s cancer-drug setback - South China Morning Post